Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SILK -37.2% (guides Q3 and FY23 revs below consensus; also CEO to retire), ETWO -19.4% (also CEO steps down), LXFR -11.6% (Q3 guidance)
Other news:
- HYLN -39.5% (hires advisors to explore options for its powertrain business)
- DVA -15.1% (showing weakness pre-market following Novo Nordisk (NVO) decision stop the once-weekly injectable semaglutide kidney outcomes trial)
- FMS -15.1% (showing weakness pre-market following Novo Nordisk (NVO) decision stop the once-weekly injectable semaglutide kidney outcomes trial)
- MOB -14.4% (files for $50 mln mixed securities shelf offering)
- PSNY -8.3% (files $1 bln mixed shelf offering)
- BAX -7.6% (showing weakness pre-market following Novo Nordisk (NVO) decision stop the once-weekly injectable semaglutide kidney outcomes trial) NOG -5.4% (prices offering of 6.5 mln shares of common stock for gross proceeds of $252.7 mln)
- XOM -2.7% (ExxonMobil (XOM) announces merger with PXD in an all-stock transaction valued at $253/share)
- IRON -2% (to sell up to $59.7 mln of its common stock)
- AMK -1.9% (provides Sept update)
- CWBC -1.8% (Central Valley Bancorp and Community West Bancshares (CWBC) to merge)
- SNX -1.7% (prices secondary offering of common stock and concurrent share repurchase)
- NGMS -1.2% (issues statement regarding Israel: entire business in region continues to operate normally)
- GATO -1% (reports Q3 production)
Analyst comments:
- PTLO -1.5% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- ANET -1.2% (downgraded to Neutral from Overweight at Piper Sandler)
- OLN -1.2% (downgraded to Equal Weight from Overweight at Barclays)
- FLT -1.1% (downgraded to Neutral from Outperform at Robert Baird)